Seek Returns logo

NVS vs. PODD: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at NVS and PODD, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

NVS trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, PODD is a standard domestic listing.

SymbolNVSPODD
Company NameNovartis AGInsulet Corporation
CountrySwitzerlandUnited States
GICS SectorHealth CareHealth Care
GICS IndustryPharmaceuticalsHealth Care Equipment & Supplies
Market Capitalization244.23 billion USD23.16 billion USD
ExchangeNYSENasdaqGS
Listing DateNovember 7, 1996May 15, 2007
Security TypeADRCommon Stock

Historical Performance

This chart compares the performance of NVS and PODD by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

NVS vs. PODD: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolNVSPODD
5-Day Price Return1.74%0.46%
13-Week Price Return9.29%2.49%
26-Week Price Return4.27%15.98%
52-Week Price Return1.76%77.21%
Month-to-Date Return8.25%14.08%
Year-to-Date Return14.95%26.02%
10-Day Avg. Volume2.68M0.60M
3-Month Avg. Volume3.20M0.77M
3-Month Volatility17.09%28.67%
Beta0.901.42

Profitability

Return on Equity (TTM)

NVS

32.56%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

In the upper quartile for the Pharmaceuticals industry, NVS’s Return on Equity of 32.56% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

PODD

18.43%

Health Care Equipment & Supplies Industry

Max
34.53%
Q3
19.38%
Median
9.52%
Q1
4.86%
Min
-7.58%

PODD’s Return on Equity of 18.43% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.

NVS vs. PODD: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Net Profit Margin (TTM)

NVS

24.90%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

A Net Profit Margin of 24.90% places NVS in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

PODD

10.01%

Health Care Equipment & Supplies Industry

Max
23.34%
Q3
13.06%
Median
9.53%
Q1
5.96%
Min
-3.87%

PODD’s Net Profit Margin of 10.01% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.

NVS vs. PODD: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Operating Profit Margin (TTM)

NVS

30.03%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

An Operating Profit Margin of 30.03% places NVS in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

PODD

12.01%

Health Care Equipment & Supplies Industry

Max
29.44%
Q3
17.80%
Median
13.95%
Q1
8.73%
Min
-3.56%

PODD’s Operating Profit Margin of 12.01% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.

NVS vs. PODD: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Profitability at a Glance

SymbolNVSPODD
Return on Equity (TTM)32.56%18.43%
Return on Assets (TTM)13.32%7.21%
Net Profit Margin (TTM)24.90%10.01%
Operating Profit Margin (TTM)30.03%12.01%
Gross Profit Margin (TTM)76.12%70.74%

Financial Strength

Current Ratio (MRQ)

NVS

0.82

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

NVS’s Current Ratio of 0.82 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

PODD

2.26

Health Care Equipment & Supplies Industry

Max
4.90
Q3
3.05
Median
2.14
Q1
1.49
Min
0.86

PODD’s Current Ratio of 2.26 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.

NVS vs. PODD: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Debt-to-Equity Ratio (MRQ)

NVS

0.77

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

NVS’s Debt-to-Equity Ratio of 0.77 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

PODD

0.96

Health Care Equipment & Supplies Industry

Max
1.49
Q3
0.71
Median
0.45
Q1
0.14
Min
0.00

PODD’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.96. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

NVS vs. PODD: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Interest Coverage Ratio (TTM)

NVS

22.55

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

NVS’s Interest Coverage Ratio of 22.55 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

PODD

33.28

Health Care Equipment & Supplies Industry

Max
58.29
Q3
25.56
Median
9.06
Q1
3.60
Min
-28.92

PODD’s Interest Coverage Ratio of 33.28 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

NVS vs. PODD: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Financial Strength at a Glance

SymbolNVSPODD
Current Ratio (MRQ)0.822.26
Quick Ratio (MRQ)0.621.55
Debt-to-Equity Ratio (MRQ)0.770.96
Interest Coverage Ratio (TTM)22.5533.28

Growth

Revenue Growth

NVS vs. PODD: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

NVS vs. PODD: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

NVS

3.29%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

NVS’s Dividend Yield of 3.29% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

PODD

0.00%

Health Care Equipment & Supplies Industry

Max
4.05%
Q3
1.76%
Median
0.71%
Q1
0.00%
Min
0.00%

PODD currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

NVS vs. PODD: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Dividend Payout Ratio (TTM)

NVS

102.24%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

NVS’s Dividend Payout Ratio of 102.24% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

PODD

0.00%

Health Care Equipment & Supplies Industry

Max
160.00%
Q3
72.47%
Median
27.49%
Q1
0.00%
Min
0.00%

PODD has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

NVS vs. PODD: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Dividend at a Glance

SymbolNVSPODD
Dividend Yield (TTM)3.29%0.00%
Dividend Payout Ratio (TTM)102.24%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

NVS

17.43

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

NVS’s P/E Ratio of 17.43 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

PODD

98.83

Health Care Equipment & Supplies Industry

Max
73.48
Q3
51.69
Median
34.31
Q1
25.74
Min
11.47

At 98.83, PODD’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Health Care Equipment & Supplies industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

NVS vs. PODD: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Price-to-Sales Ratio (TTM)

NVS

4.34

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

NVS’s P/S Ratio of 4.34 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

PODD

9.89

Health Care Equipment & Supplies Industry

Max
9.53
Q3
5.26
Median
3.39
Q1
2.13
Min
0.00

With a P/S Ratio of 9.89, PODD trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

NVS vs. PODD: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Price-to-Book Ratio (MRQ)

NVS

6.00

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

NVS’s P/B Ratio of 6.00 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

PODD

15.11

Health Care Equipment & Supplies Industry

Max
10.85
Q3
5.98
Median
3.48
Q1
2.43
Min
0.69

At 15.11, PODD’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

NVS vs. PODD: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Health Care Equipment & Supplies industry benchmarks.

Valuation at a Glance

SymbolNVSPODD
Price-to-Earnings Ratio (TTM)17.4398.83
Price-to-Sales Ratio (TTM)4.349.89
Price-to-Book Ratio (MRQ)6.0015.11
Price-to-Free Cash Flow Ratio (TTM)14.1661.02